Jade Biosciences

Company snapshot

Jade Biosciences is a clinical-stage company developing a pipeline of potentially best-in-class therapies aimed at transforming the standard of care for patients living with autoimmune diseases.

• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 US patent(s) indexed to this assignee profile.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Jade Biosciences. Not investment advice.

• What is Jade Biosciences?

  Jade Biosciences is a pharma organization headquartered in Waltham, USA. It trades on NYSE under ticker JBIO. Primary therapeutic focus areas include IgA Nephropathy, Rhematoid Arthritis. NovaPharmaNews links 4 clinical program(s), 0 drug profile(s), and 2 patent record(s) to thi

• Is Jade Biosciences publicly traded?

  Yes. Jade Biosciences is listed with ticker JBIO on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Jade Biosciences develop or market?

  We link 1 drug profile(s) where Jade Biosciences is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/jade-biosciences#company-drugs.

• What are the latest developments for Jade Biosciences?

  In the last 12 months our linked public records show 4 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Jade Biosciences focus on?

  Jade Biosciences focuses on IgA Nephropathy, Rhematoid Arthritis based on our analysis of their pipeline programs and drug development activities.